The Covid Sanofi-Gsk vaccine, “arrives at the end of 2021”

Published on: 11/12/2020 7:31 AM

Sanofi and GSK announce a delay in their schedule for a COVID-19 vaccine based on recombinant proteins to improve the immune response in the elderly. In fact, it is explained in a note, “The intermediate results of the phase 1/2 study showed an immune response comparable to that of patients cured of COVID-19 in adults 18 to 49 years, but a low immune response in elderly probably due to insufficient antigen concentration “.

Therefore, the companies are planning a Phase 2b study with an improved antigen formulation, beginning in February 2021, including a proposed comparison with a licensed COVID-19 vaccine. Product availability is now expected in the fourth quarter of 2021 pending the successful completion of the development plan.